Pneumocystis Pneumonia: Current Concepts in Pathogenesis, Diagnosis, and Treatment

Bryan J. Krajicek; Charles F. Thomas; Andrew H. Limper

doi:10.1016/j.ccm.2009.02.005

Pneumocystis Pneumonia: Current Concepts in Pathogenesis, Diagnosis, and Treatment

Bryan J. Krajicek, Charles F. Thomas, Andrew H. Limper

Research output: Contribution to journal › Review article › peer-review

52 Scopus citations

Abstract

Pneumocystis pneumonia (PCP) is an infection of the lungs caused by the opportunistic fungal genus Pneumocystis. In humans, PCP is a serious and potentially life-threatening infection occurring in immunocompromised individuals, particularly those who have AIDS, or following immune suppression from malignancy, organ transplantation, or therapies for inflammatory diseases. Several recent studies have contributed to understanding of the biology and pathogenesis of the organism yielding new diagnostic approaches and therapeutic targets. Although trimethoprim-sulfamethoxazole remains the mainstay of prophylaxis and treatment, ongoing concerns for emerging Pneumocystis resistance supports the continuing investigation for novel therapeutic agents.

Original language	English (US)
Pages (from-to)	265-278
Number of pages	14
Journal	Clinics in Chest Medicine
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/j.ccm.2009.02.005
State	Published - Jun 1 2009
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.ccm.2009.02.005

Fingerprint Dive into the research topics of 'Pneumocystis Pneumonia: Current Concepts in Pathogenesis, Diagnosis, and Treatment'. Together they form a unique fingerprint.

Cite this

@article{3a56c923e63e4d1babe48aabea58ada5,

title = "Pneumocystis Pneumonia: Current Concepts in Pathogenesis, Diagnosis, and Treatment",

abstract = "Pneumocystis pneumonia (PCP) is an infection of the lungs caused by the opportunistic fungal genus Pneumocystis. In humans, PCP is a serious and potentially life-threatening infection occurring in immunocompromised individuals, particularly those who have AIDS, or following immune suppression from malignancy, organ transplantation, or therapies for inflammatory diseases. Several recent studies have contributed to understanding of the biology and pathogenesis of the organism yielding new diagnostic approaches and therapeutic targets. Although trimethoprim-sulfamethoxazole remains the mainstay of prophylaxis and treatment, ongoing concerns for emerging Pneumocystis resistance supports the continuing investigation for novel therapeutic agents.",

author = "Krajicek, {Bryan J.} and Thomas, {Charles F.} and Limper, {Andrew H.}",

year = "2009",

month = jun,

day = "1",

doi = "10.1016/j.ccm.2009.02.005",

language = "English (US)",

volume = "30",

pages = "265--278",

journal = "Clinics in Chest Medicine",

issn = "0272-5231",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Pneumocystis Pneumonia

T2 - Current Concepts in Pathogenesis, Diagnosis, and Treatment

AU - Krajicek, Bryan J.

AU - Thomas, Charles F.

AU - Limper, Andrew H.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Pneumocystis pneumonia (PCP) is an infection of the lungs caused by the opportunistic fungal genus Pneumocystis. In humans, PCP is a serious and potentially life-threatening infection occurring in immunocompromised individuals, particularly those who have AIDS, or following immune suppression from malignancy, organ transplantation, or therapies for inflammatory diseases. Several recent studies have contributed to understanding of the biology and pathogenesis of the organism yielding new diagnostic approaches and therapeutic targets. Although trimethoprim-sulfamethoxazole remains the mainstay of prophylaxis and treatment, ongoing concerns for emerging Pneumocystis resistance supports the continuing investigation for novel therapeutic agents.

AB - Pneumocystis pneumonia (PCP) is an infection of the lungs caused by the opportunistic fungal genus Pneumocystis. In humans, PCP is a serious and potentially life-threatening infection occurring in immunocompromised individuals, particularly those who have AIDS, or following immune suppression from malignancy, organ transplantation, or therapies for inflammatory diseases. Several recent studies have contributed to understanding of the biology and pathogenesis of the organism yielding new diagnostic approaches and therapeutic targets. Although trimethoprim-sulfamethoxazole remains the mainstay of prophylaxis and treatment, ongoing concerns for emerging Pneumocystis resistance supports the continuing investigation for novel therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=64249144493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249144493&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2009.02.005

DO - 10.1016/j.ccm.2009.02.005

M3 - Review article

C2 - 19375633

AN - SCOPUS:64249144493

VL - 30

SP - 265

EP - 278

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

SN - 0272-5231

IS - 2

ER -